A

Aldeyra Therapeutics
D

ALDX

5.38000
USD
0.08
(1.41%)
مغلق
حجم التداول
37,805
الربح لكل سهم
-1
العائد الربحي
-
P/E
-6
حجم السوق
323,044,951
أصول ذات صلة
A
AMRN
0.600
(3.98%)
15.690 USD
B
BLDP
0.15500
(8.42%)
1.99500 USD
C
CAPR
0.20500
(2.64%)
7.96500 USD
C
CLRB
-0.02000
(-0.46%)
4.35000 USD
E
ESCA
-0.370
(-2.97%)
12.070 USD
G
GERN
0.00000
(0.00%)
1.45500 USD
GILD
GILD
-0.680
(-0.57%)
118.320 USD
H
HALO
1.780
(2.72%)
67.300 USD
I
IONS
0.910
(2.12%)
43.780 USD
NVS
NVS
2.080
(1.70%)
124.210 USD
O
OPK
0.01000
(0.74%)
1.36500 USD
S
SLDB
-0.06000
(-0.97%)
6.12000 USD
VRTX
VRTX
2.49
(0.64%)
392.97 USD
C
CBIO
-0.100
(-0.72%)
13.800 USD
المزيد
الأخبار المقالات

العنوان: Aldeyra Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.